Trial · NCT07891949
Plasmonic PhotoThermal Therapy (PPTT) With Glucose-Coated Gold Nanoparticles (TSK-001) in Patients With Nodular Basal Cell Carcinoma (nBCC)
NCT07891949, Not applicable, Not yet recruiting, Torskal SAS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Plasmonic PhotoThermal Therapy (PPTT) With Glucose-Coated Gold Nanoparticles (TSK-001) in Patients With Nodular Basal Cell Carcinoma (nBCC). Trials, record NCT07891949. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891949
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Plasmonic PhotoThermal Therapy (PPTT) With Glucose-Coated Gold Nanoparticles (TSK-001) in Patients With Nodular Basal Cell Carcinoma (nBCC)
- NCT number
- NCT07891949
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 78 participants, estimated
- Lead sponsor
- Torskal SAS
- Conditions
- Nodular BCC
- Interventions
TSK-001. Injectable solution of glucose-functionalised plasmonic gold nanoparticles (0.3 mg in 1 mL water for injection) for intratumoural administration., 808 nm near-infrared (NIR) diode laser (Hyper Diode 808)
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | P1. Number of Participants With Treatment-Emergent Adverse Events (Parts 1 and 2) | Day 1 (D1) to Day 180 | Description : Number of participants with at least one treatment-emergent adverse event (TEAE). Severity is graded per CTCAE v5.0 and relationship to TSK-001 and/or NIR irradiation is assessed by the investigator. Results will be reported overall, by maximum severity grade and by relationship category. Unit : participants |
| Primary | P2. Number of Participants With Clinically Significant Laboratory Abnormalities (Parts 1 and 2) | from baseline to Day 180 | Description : Number of participants with at least one post-baseline haematology or clinical chemistry value judged clinically significant by the investigator. Unit : participants |
| Primary | P3. Number of Participants With Clinically Significant Vital Sign Abnormalities (Parts 1 and 2) | baseline to Day 360 | Description : Number of participants with at least one post-baseline vital sign value (blood pressure, heart rate, body temperature, respiratory rate) judged clinically significant by the investigator. Unit : participants |
| Primary | P4. Number of Participants With Clinically Significant 12-Lead ECG Abnormalities (Parts 1 and 2) | baseline to Day 360 | Description : Number of participants with at least one post-baseline 12-lead ECG finding judged clinically significant by the investigator. Unit : participants |
| Primary | P5. Maximum Local Skin Response (LSR) Composite Score (Parts 1 and 2) | Day 1 to Day 360 | Description : The LSR Grading Scale rates 6 signs at the treated site (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosion/ulceration), each from 0 (absent) to 4 (severe). The composite score is the sum of the 6 grades (range 0-24; higher scores indicate more severe reactions). The highest composite score recorded for each participant over the time frame will be reported. Unit : score on a scale |
| Primary | P6. Number of Participants With Pigmentation Changes or Scarring at the Treated Site (Parts 1 and 2) | Day 1 to Day 360 | Description : Number of participants with hypopigmentation, hyperpigmentation or scarring at the treated site, as assessed by the investigator. Unit : participants |
| Primary | P7. Maximum Pain Intensity on a Visual Analogue Scale (Parts 1 and 2) | Day 1 to Day 360 | Description : Pain at the treated site is self-rated by the participant on a 100 mm VAS (0 mm = no pain, 100 mm = worst imaginable pain). The highest score recorded for each participant will be reported. Unit : mm |
| Primary | P8. Maximum Lesion Temperature During NIR Irradiation (Parts 1 and 2) | during irradiation on Day 1 (and Day 15 in Part 2) | Description : Highest lesion surface temperature measured by infrared thermography during the irradiation session(s). For participants treated twice (Part 2), the highest value across both sessions will be reported. Unit : °C |
| Primary | P9. Percentage of Participants With Complete Response (Part 3) | Day 29 | Description : Complete response is defined as disappearance of the target lesion according to RECIST v1.1, measured with digital callipers. Unit : percentage of participants |
| Primary | P10. Percentage of Participants With No Residual Tumour on Histology (Part 3) | At excision (Day 29 to Day 180) or Day 180 | Description : Absence of residual viable tumour cells on histology of the excised lesion, or of a punch biopsy if no excision is performed. Unit : percentage of participants |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891949
GET https://conductscience.org/api/trials/v1/NCT07891949/registered?page=2